A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2017
At a glance
- Drugs ABBV 428 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 10 Feb 2017 Planned number of patients changed from 142 to 172.
- 10 Feb 2017 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
- 23 Nov 2016 Status changed from not yet recruiting to recruiting.